FluroTech Ltd. (TEST.V)
| Previous Close | 0.1800 |
| Open | 0.1850 |
| Bid | 0.1800 x 0 |
| Ask | 0.1850 x 0 |
| Day's Range | 0.1850 - 0.1850 |
| 52 Week Range | 0.0850 - 0.8500 |
| Volume | 4,170 |
| Avg. Volume | 211,496 |
| Market Cap | 22.313M |
| Beta (5Y Monthly) | -1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0460 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
FluroTest Announces Pre-Emergency Use Authorization Filing with FDA; Provides Executive Update on Program Progress
CALGARY, Alberta, July 12, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced it has filed its Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA). The Pre-EUA submission is the Company’s latest step taken as it
- GlobeNewswire
FluroTest Diagnostic Systems Featured in Grand View Research Report Exploring Growth of COVID-19 Saliva Screening Test Potential Market
CALGARY, Alberta, June 17, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to be recognized in Grand View Research’s June 2021 report: COVID-19 Saliva Screening Test Potential Market. According to the report, the global COVID-19 saliva screening test potentia
- CNW Group
Former US Assistant Health Secretary Dr. Joxel Garcia Joins FluroTest as Chief Medical Officer and Executive Team Member
FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce the appointment of former U.S. Public Health Service and Four-Star Admiral Joxel Garcia, M.D. to Chief Medical Officer (CMO). Dr. Garcia will be responsible for expanding FluroTest's domestic and international reach while dr
